Moberg Pharma Q4’23: Results in line – focus on Swedish launch

Research Note



Redeye saw a report that came in as expected regarding the results. There were, as expected, no sales in the quarter, and costs were in line with our expectations. The main event in the quarter was the preparation of the official launch of Terclara in Sweden in February and the completion of the enrollment in the North American Phase 3 study.


Mats Hyttinge

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.